Wikisage, the free encyclopedia of the second generation, is digital heritage
Doripenem: Difference between revisions
Jump to navigation
Jump to search
(→ATC) |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
<ref>https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022106s012lbl.pdf</ref> | <ref>https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022106s012lbl.pdf</ref> | ||
|| | || | ||
{{wikidata|Q411552}} | |||
|} | |} | ||
==ATC== | ==ATC== | ||
<ref>[https://karmel.miraheze.org/m/6Sy | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
|colspan=2| <center> | |||
[[File:Doripenem_vert1.jpg|292px]] | |||
: [[wikipedia:doripenem|doripenem]] | |||
<ref>[https://www.whocc.no/atc_ddd_index/?code=J01DH04 J01DH04]</ref></center> | |||
|} | |||
<ref>[https://karmel.miraheze.org/m/6Sy karmel(miraheze) es:Doripenem]</ref> | |||
{{refs}} | {{refs}} | ||
Latest revision as of 21:28, 2 September 2021
Doripenem is a beta-lactam antibiotic agent belonging to the carbapenem group
|
Seizures have been reported during treatment with doripenem (see section 6.2). In clinical trials, doripenem-treated patients with pre-existing central nervous system (CNS) disorders (e.g. stroke or history of seizures), patients with compromised renal function and patients given doses greater than 500 mg every 8 hours appear to be at greater risk for developing seizures [1] |
ATC
|
| References: |